nach oben

Erschienen in:

31.05.2014 | Fortbildung

Oberstes Ziel ist Anfallsfreiheit

State of the Art bei der antikonvulsiven Pharmakotherapie

verfasst von: Prof. Dr. med. Bernhard J. Steinhoff

Erschienen in: Pädiatrie | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Trotz der Einführung und Verbesserung verschiedenster Therapiemöglichkeiten, v. a. der Epilepsiechirurgie, aber auch der ketogenen Diät oder Stimulationsverfahren, ist und bleibt die medikamentöse Behandlung die Standardtherapie bei den meisten Epilepsiepatienten. Dabei hat sich durch die Generation neuerer Antikonvulsiva seit 1992 allerdings nicht wirklich nennenswert häufiger eine dauerhafte und verlässliche Anfallsfreiheit erreichen lassen.

Arif H, Buchanan R, Pierro J et al (2010) Comparative effectiveness of 10 antiepileptic drugs in older adults with epilepsy. Arch Neurol 67:408–415PubMedCrossRef

Baulac M, Brodie MJ, Patten A et al (2012) Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol 11:579–588PubMedCrossRef

Baumgartner C, Beyenburg S, Dennig D et al (2012) Erster epileptischer Anfall und Epilepsien im Erwachsenenalter. In: Diener HC, Weimar C, Berlit P et al (Hrsg) Leitlinien für Diagnostik und Therapie in der Neurologie, 5. Aufl. Thieme, Stuttgart, S 28–47

Beghi E, De Maria G, Gobbi G, Veneselli E (2006) Diagnosis and treatment of the first epileptic seizure: guidelines of the Italian League against Epilepsy. Epilepsia 47(Suppl 5):2–8PubMedCrossRef

Beghi E, Gatti G, Tonini C et al (2003) Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. Epilepsy Res 57:1–13PubMedCrossRef

Berg AT, Berkovic SF, Brodie MJ et al (2010) Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia 51:676–685PubMedCrossRef

Brodie MJ, Overstall PW, Giorgi L (1999) Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 37:81–87PubMedCrossRef

Brodie MJ, Perucca E, Ryvlin P et al (2007) Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 68:402–408PubMedCrossRef

Brodie MJ, Richens A, Yuen AW (1995) Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 345:476–479PubMedCrossRef

10.

Callaghan BC, Anand K, Hesdorffer D et al (2007) Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol 62:382–389PubMedCrossRef

11.

Chadwick D (1999) Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group. Lancet 354:13–19PubMedCrossRef

12.

Chadwick DW, Anhut H, Greiner MJ et al (1998) A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77. Neurology 51:1282–1288PubMedCrossRef

13.

Christe W, Krämer G, Vigonius U et al (1997) A double-blind controlled clinical trial of oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 26:451–460PubMedCrossRef

14.

(o A) (1989) Commission on classification and terminology of the international league against epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 30:389–399

15.

Dam M, Ekberg R, Loyning Y et al (1989) A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 3:70–76PubMedCrossRef

16.

Deckers CL, Hekster YA, Keyser A et al (2001) Monotherapy versus polytherapy for epilepsy: a multicenter double-blind randomized study. Epilepsia 42:1387–1394PubMedCrossRef

17.

Diaz RA, Sancjo J, Serratosa J (2008) Antiepileptic drug interactions. Neurologist 14(6 Suppl 1):S55–S65PubMedCrossRef

18.

Engel J Jr, McDermott MP, Wiebe S et al (2012) Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial. JAMA 307:922–930PubMedCrossRef

19.

Ficker DM, Privitera M, Krauss G et al (2005) Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine. Neurology 65:593–595PubMedCrossRef

20.

French JA, Kanner AM, Bautista J et al (2004) Efficacy and tolerability of the new antiepileptic drugs, II: treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 45:410–423PubMedCrossRef

21.

French JA, Kanner AM, Bautista J et al (2004) Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 27:1252–1260CrossRef

22.

French JA, Kanner AM, Bautista J et al (2004) Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 27:1261–1273CrossRef

23.

Fröscher W, Steinhoff BJ (2011) Laborkontrollen in der Pharmakotherapie von Epilepsien. Z Epileptol 24:12–25CrossRef

24.

Glauser TA, Ben-Menachem E, Bourgeois B et al (2013) Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 54:551–563PubMedCrossRef

25.

Glauser TA, Cnaan A, Shinnar S et al (2010) Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 352:790–799CrossRef

26.

Glauser TA, Cnaan A, Shinnar S et al (2013) Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia 54:141–155PubMedCentralPubMedCrossRef

27.

Gueler N, Krämer G (2009) Behandlungsstrategien mit Antiepileptika, Ein- und Ausschleichen. Z Epileptol 22:13–19CrossRef

28.

Guerreiro MM, Vigonius U, Pohlmann H et al (1997) A double-blind controlled, clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 27:205–213PubMedCrossRef

29.

Guerrini R, Dravet C, Genton P et al (1998) Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 39:508–512PubMedCrossRef

30.

Hauptmann A (1912) Luminal bei Epilepsie. Munch Med Wochenschr 59:1907–1909

31.

Heller AJ, Chesterman P, Elwes RD et al (1995) Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. J Neurol Neurosurg Psychiatry 58:44–50PubMedCentralPubMedCrossRef

32.

Helmers SL, Paradis PE, Manjunath R et al (2010) Economic burden associated with the use of generic antiepileptic drugs in the United States. Epilepsy Behav 18:437–444PubMedCrossRef

33.

Kälviäinen R, Aikia M, Saukkonen AM et al (1995) Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study. Arch Neurol 52:989–996PubMedCrossRef

34.

Krauss GL, Caffo B, Chang Y-T et al (2011) Assessing bioequivalence of generic antiepileptic drugs. Ann Neurol 70:221–228PubMedCrossRef

35.

Kwan P, Arzimanoglou A, Berg AT et al (2010) Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 51:1069–1077PubMedCrossRef

36.

Kwan P, Brodie MJ (2000) Early identification of refractory epilepsy. N Engl J Med 342:314–319PubMedCrossRef

37.

Kwan P, Brodie MJ (2000) Epilepsy after the first drug fails: substitution or add-on? Seizure 9:464–468PubMedCrossRef

38.

Kwan P, Brodie MJ, Kälviäinen R et al (2011) Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 2, double-blind, randomised, parallel-group trial. Lancet Neurol 10:881–890PubMedCrossRef

39.

Luciano AL, Shorvon SD (2007) Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol 62:375–381PubMedCrossRef

40.

Marson AG, Al-Kharusi AM, Alwaidh M et al (2007) The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 369:1000–1015PubMedCentralPubMedCrossRef

41.

Marson AG, Al-Kharusi AM, Alwaidh M et al (2007) The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 369:1016–1026PubMedCentralPubMedCrossRef

42.

Marson A, Jacoby A, Johnson A et al (2005) Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet 365:2007–2013PubMedCrossRef

43.

Mattson RH, Cramer JA, Collins JF et al (1985) Comparison of carbamazepine, phenobarbital, phenytoin and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 313:145–151PubMedCrossRef

44.

Mattson RH, Cramer JA, Collins JF (1992) The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. A comparison of valproate with carbamazepine for the treatment of complex partial and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 327:765–771PubMedCrossRef

45.

Mumford JP, Cannon DJ (1994) Vigabatrin. Epilepsia 35(Suppl 5):S25–S28PubMedCrossRef

46.

Nunes VD, Sawyer L, Neilson J et al (2012) Diagnosis and management of the epilepsies in adults and children: summary of updated NICE guidance. BMJ 344:e281PubMedCrossRef

47.

Porter RJ (1995) How to use antiepileptic drugs. In: Von Levy RH, Mattson RH, Meldrum BS (Hrsg) Antiepileptic drugs, 4. Aufl. Raven Press, New York, S 137–148

48.

Privitera MD, Brodie MJ, Mattson RH et al (2003) Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 107:165–175PubMedCrossRef

49.

Relling MV, Pui CH, Sandlund JT et al (2000) Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 356:285–290PubMedCrossRef

50.

Reunanen M, Dam M, Yuen AW (1996) A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res 23:149–155PubMedCrossRef

51.

Reynolds EH (1983) Mental effects of antiepileptic medication: a review. Epilepsia 24(Suppl 2):85–95CrossRef

52.

Reynolds EH, Shorvon SD (1981) Monotherapy or polytherapy for epilepsy. Epilepsia 22:1–10PubMedCrossRef

53.

Rosenow F, Schade-Bettinger C, Burchardi N et al (2012) The LaLiMo trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy–an open-label, prospective, randomised controlled multicenter study. J Neurol Neurosurg Psychiatry 83:1093–1098PubMedCrossRef

54.

Rowan AJ, Ramsay RE, Collins JF et al (2005) New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 64:1868–1873PubMedCrossRef

55.

Sake J-K, Hebert D, Isojärvi J et al (2010) A pooled analysis of lacosamide clinical trial data grouped by mechanisms of action of concomitant antiepileptic drugs. CNS Drugs 24:1055–1068PubMedCrossRef

56.

Schmidt D (1983) Pharmacotherapy of epilepsy–current problems and controversies. Fortschr Neurol Psychiat 51:363–386PubMedCrossRef

57.

Schmidt D (2009) Drug treatment of epilepsy: options and limitations. Epilepsy Behav 15:56–65PubMedCrossRef

58.

Sheth RD, Harden CL (2007) Screening for bone health in epilepsy. Epilepsia 48(Suppl 9):39–41PubMedCrossRef

59.

Shorvon SD, Reynolds EH (1977) Unnecessary polypharmacy for epilepsy. Br Med J 1(6077):1635–1637PubMedCentralPubMedCrossRef

60.

Shorvon SD, Reynolds EH (1979) Reduction in polypharmacy for epilepsy. Br Med J 2(6197):1023–1025PubMedCentralPubMedCrossRef

61.

Steiner TJ, Dellaportas CL, Findley LJ et al (1999) Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 40:601–607PubMedCrossRef

62.

Steinhoff BJ (1992) Antiepileptic therapy with bromides–historical and actual importance. J Hist Neurosci 1:119–123PubMedCrossRef

63.

Steinhoff BJ (2005) Der Epilepsiepatient in der Praxis. ComMed Verlagsagentur, Basel

64.

Steinhoff BJ (2009) Oxcarbazepine extended-release formulation in epilepsy. Expert Rev Clin Pharmacol 2:155–162PubMedCrossRef

65.

Steinhoff BJ (2009) Verzögert freigesetztes Oxcarbazepin–Überblick und klinische Erfahrungen. Z Epileptol 22:2–8CrossRef

66.

Steinhoff BJ (2012) Pharmakotherapie der Epilepsie. Klin Neurophys 43:131–137CrossRef

67.

Steinhoff BJ, Fröscher W (2011) Bedeutung der Serumkonzentrationen von Antikonvulsiva. Z Epileptol 24:6–11CrossRef

68.

Steinhoff BJ, Kurth C, Dennig D (2012) Levetiracetam bei generalisierten Epilepsien des Erwachsenenalters. Praktische Erfahrungen mit dem Einsatz außerhalb der Zulassung. Z Epileptol 25:118–124CrossRef

69.

Steinhoff BJ, Runge U, Witte OW et al (2009) Substitution of anticonvulsant drugs. Ther Clin Risk Manag 5:449–457PubMedCentralPubMedCrossRef

70.

Steinhoff BJ, Ueberall MA, Siemes H et al (2005) The LAM-SAFE Study: lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalized epilepsies in adolescents and adults. Seizure 14:597–605PubMedCrossRef

71.

Steinhoff BJ, Maren Staack A, Wisniewski I (2012) Seizure control with antiepileptic drug therapy in 517 consecutive adult outpatients at the Kork Epilepsy Centre. Epileptic Disord 14:379–387PubMed

72.

Steinhoff BJ, Stefan H, Schulze-Bonhage A et al (2012) Retardiertes vs. Schnell freisetzendes Oxcarbazepin bei therapierefraktärer fokaler Epilepsie. Eine offene multizentrische, randomisierte kontrollierte Studie. Nervenarzt 83:1292–1299PubMedCrossRef

73.

Steinhoff BJ, Wendling A-S (2009) Short-term impact of the switch from immediate-release to extended-release oxcarbazepine in epilepsy patients on high dosages. Epilepsy Res 87:256–259PubMedCrossRef

74.

Tanganelli P, Regetsa G (1996) Vigabatrin versus carbamazepine monotherapy in newly diagnosed focal epilepsy: a randomised response conditional cross-over study. Epilepsy Res 25:257–262PubMedCrossRef

75.

Tomson T, Steinhoff BJ (2012) Principles of drug treatment in adults. Handb Clin Neurol 108:683–698PubMedCrossRef

76.

Trinka E, Marson AG, Van Paeschen W et al (2012) KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy. J Neurol Neurosurg Psychiatry (Epub ahead of print)

77.

Warner G, Figgitt DP (2005) Pregabalin: as adjunctive treatment of partial seizures. CNS Drugs 19:265–272PubMedCrossRef

78.

Wiebe S, Blume WT, Girvin JP et al (2001) A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med 345:311–318PubMedCrossRef

Titel: Oberstes Ziel ist Anfallsfreiheit
State of the Art bei der antikonvulsiven Pharmakotherapie
verfasst von: Prof. Dr. med. Bernhard J. Steinhoff
Publikationsdatum: 31.05.2014
Verlag: Urban & Vogel
Erschienen in: Pädiatrie / Ausgabe 3/2014
Print ISSN: 1867-2132
Elektronische ISSN: 2196-6443
DOI: https://doi.org/10.1007/s15014-014-0377-5

Neu im Fachgebiet Pädiatrie

18.04.2024 | Spinale Muskelatrophien | Nachrichten

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Oberstes Ziel ist Anfallsfreiheit

State of the Art bei der antikonvulsiven Pharmakotherapie

Zusammenfassung

Neu im Fachgebiet Pädiatrie

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Zunahme von Geschlechtsinkongruenz und -dysphorie registriert

Intrakapsuläre Tonsillektomie gewinnt an Boden

Update Pädiatrie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2014

Kind zu dick – und die Eltern sehen‘s nicht

Indexierte Verträge sichern Mietanpassung

Meist infolge einer Grunderkrankung

Fundstücke

Eine Brücke zwischen den Fachgebieten

Vereinfachung der HPV-Impfung in Sicht

Neu im Fachgebiet Pädiatrie

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Zunahme von Geschlechtsinkongruenz und -dysphorie registriert

Intrakapsuläre Tonsillektomie gewinnt an Boden

Update Pädiatrie